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Abstract: Esomeprazole (Nexium; AstraZeneca), the S-isomer of omeprazole, is the 
first proton pump inhibitor (PPI) to be developed as an optical isomer. Compared with 
omeprazole, esomeprazole has an improved pharmacokinetic profile with regards to CYP2C19 
(S-mephenytoin 4′-hydroxylase) genotype, showing increased systemic exposure and less 
interindividual variability. Further, esomeprazole is a more potent acid inhibitor than other 
currently available PPIs and is therefore used as a first-line drug for acid-related diseases. 
While esomeprazole has been available in a number of countries worldwide, the compound 
only received authorized permission to be marketed in Japan in September 2011. The standard 
esomeprazole dose in Japan for the treatment of peptic ulcers and gastroesophageal reflux 
disease (GERD) is 20 mg. Other advised dosages are 10 mg for nonerosive reflux disease and 
20 mg twice-daily dosing for eradication of Helicobacter pylori. In Japanese, the effective rate 
of esomeprazole 20 mg during 24 weeks for GERD patients is 92.0% (88.0%–96.0%), while 
the prevention of peptic ulcer development using 20 mg for 24 weeks in patients treated with 
nonsteroidal anti-inflammatory drugs is 96.0% (92.8%–99.1%). Although clinical data are 
limited, the usefulness of esomeprazole is expected in Japanese subjects given the reduced 
prevalence of CYP2C19 rapid metabolizers in Japan compared with Western countries.
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Introduction
A wide number of proton pump inhibitors (PPIs) have been developed for the treatment 
of acid-related diseases. PPIs are currently the first-line treatment against acid-related 
diseases such as gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), 
nonerosive reflux disease (NERD) and Zollinger–Ellison syndrome, and are used in 
combination with antibiotics for the eradication of Helicobacter pylori.1–4 PPIs function 
by first being absorbed into the small intestine and reaching the gastric parietal cells 
via systemic circulation, where they then disturb proton pump (H+/K+-ATPase) activ-
ity by irreversibly binding to the pumps, thereby resulting in potent acid inhibition.5,6 
In Japan, four kinds of PPIs are available: omeprazole, lansoprazole, rabeprazole, 
and esomeprazole, the last of which has been approved for use in Japan only since 
September 2011. In this review, we focus on esomeprazole, newly available in Japan, 
and its efficacy in treating acid-related diseases in Japanese patients.
Characteristics of esomeprazole
PPIs are substituted benzimidazoles that exist as a racemic mixture of R- and S-isomers. 
Esomeprazole (Nexium; AstraZeneca, Wilmington, DE) is the S-isomer of the PPI 
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omeprazole and is the first single-isomer PPI to be developed 
for the treatment of acid-related diseases. In general, esome-
prazole more effectively inhibits gastric acid secretion than 
omeprazole, particularly during daytime.7–9 Esomeprazole 
differs from both its parent compound as well as other PPIs 
in that it has a lower first-pass hepatic metabolism and 
slower plasma clearance, which results in higher plasma 
concentrations.7–9 This increased systemic bioavailability 
offers potentially better clinical efficacy and more effective 
management of acid-related diseases.
In Japan, the standard dose of esomeprazole for treat-
ment is 20 mg once-daily dosing (od), which is half the 
40 mg od dose more commonly used in several Western 
countries. Overall, the Japanese national health insurance 
system permits esomeprazole use for the treatment of 
gastric ulcers for 8 weeks (20 mg od), duodenal ulcers for 
6 weeks (20 mg od), erosive GERD for 8 weeks (10–20 mg 
od), NERD for 8 weeks (10 mg od), for the treatment of 
Zollinger–Ellison syndrome (20 mg od), for the prevention 
of nonsteroidal anti-inflammatory drug (NSAID)-induced 
peptic ulcers (20 mg od), and for the eradication of H. pylori 
(20 mg twice-daily [bid]) for 7 days. However, because it 
has only recently been available in Japan, information on 
the pharmacological and clinical effects of esomeprazole in 
Japanese populations is limited.
Pharmacokinetics of esomeprazole
In human liver microsomal experiments, the metabolic rate 
significantly differed among three types of S-omeprazole 
(esomeprazole), R-omeprazole, and a racemic mixture of 
the two (omeprazole), with the metabolic rate for esome-
prazole in relation to drug metabolic enzyme being sub-
stantially lower than that for R-omeprazole or omeprazole.8 
The sum of the intrinsic clearance of all three metabolites 
(sulfone, hydroxyl, and 5-O-desmethyl metabolites) was 
14.6 and 42.5 mL/min/mg protein for esomeprazole and 
R-omeprazole, respectively (Figure 1).7 The maximum 
plasma esomeprazole concentrations (Cmax) attained with 
esomeprazole were higher than those observed for the 
other two drugs (Table 1).8 For reference, single 20 mg 
oral doses of esomeprazole generally give a Cmax value of 
0.5–1.8 mg/L within 1–3 hours of administration in Western 
populations.8–10 Respective area-under-the-curve (AUC) 
values of esomeprazole, R-omeprazole, and omeprazole 
were 1.52, 0.62, and 1.04 µmol ⋅ hour/L on Day 1 and 
2.84, 0.68, and 1.63 µmol ⋅ hour/L on Day 5. Additionally, 
the AUCs of esomeprazole at 20 and 40 mg were over 1.8 
and 5.0 times higher than values for omeprazole 20 mg,9 
suggesting that after repeated administration, the Cmax values 
of esomeprazole and omeprazole increase by approximately 
50%–80% and 40%–50%, respectively, compared with 
that on Day 1,8,10 and that the AUC levels of esomepra-
zole and omeprazole increase by approximately 80% and 
50%, respectively, while that of R-omeprazole is almost 
unchanged (Table 1).8 This change in drug exposure after 
repeated administration of esomeprazole and omeprazole 
may be due to an inhibition of cytochrome P450 (CYP) 
2C19, one of the main drug metabolic enzymes for esome-
prazole and omeprazole.
In another Phase I study of esomeprazole conducted by 
AstraZeneca in a Japanese population, the AUC and Cmax 
values on Day 5 were approximately 80%–100% higher than 
on Day 1, findings consistent with those in Western popula-
tions (Table 1).11 However, respective AUC values on Days 1 
and 5 were 3.23 and 5.99 µmol ⋅ hour/L, respectively, values 
higher than those in Western populations (Table 1). This 
discrepancy may be due to differing frequencies of different 
S-mephenytoin 4′-hydroxylase (CYP2C19) genotype status 
R-omeprazole
CYP2C19
CYP3A4
0.8 (2%)
5-O-Desmethyl
omeprazole
5-Hydroxy
omeprazole
Omeprazole
sulphone
S-omeprazole
CYP2C19
39.9 (94%)
CYP2C19
CYP2C19
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Figure 1 Clearance of R-omeprazole and S-omeprazole in relation to CYP2C19 and CYP3A4.7 Clearance was 14.6 and 42.5 µL/min/mg protein for esomeprazole and 
R-omeprazole.
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among geographic populations12–14 and to the prevalence of 
poor metabolizers (PMs) in that Phase I study.
Pharmacodynamics  
as acid-inhibiting drugs
While acid inhibition attained with esomeprazole, 
R-omeprazole, and omeprazole pharmacodynamics closely 
correlates to their respective AUC values, an observation 
true for other PPIs as well,15,16 esomeprazole tends to show 
higher AUC values and more pronounced acid suppres-
sion than its related compounds.9 In Western populations, 
esomeprazole at 40 mg maintains a percent of time of 
intragastric pH .4 for approximately 6 hours longer than 
omeprazole at 20 mg (16.8 vs 10.5 hours) and 4 hours lon-
ger than esomeprazole at 20 mg (16.8 vs 12.7 hours).9 In 
general, esomeprazole is more effective at inhibiting potent 
acid secretion at 40 mg than at 20 mg, which is why many 
Western countries have established 40 mg as the standard 
dose for the treatment of acid-related diseases. However, 
in Japanese, the respective percent of time of intragastric 
pH .4 with esomeprazole at 40 and 20 mg and omeprazole 
at 20 mg are 62.39% ± 14.40% (n = 40), 68.49% ± 8.09% 
(n = 37), and 58.91% ± 14.40% (n = 38),11 respectively, sug-
gesting little difference in acid inhibition at esomeprazole 
40 or 20 mg in Japanese. Therefore, because acid inhibi-
tion attained with esomeprazole in Japanese may be more 
potent than Western populations, esomeprazole 20 mg was 
selected as the standard dose.
In a randomized crossover study using 108 H. 
  pylori-negative subjects, the percent of time of intragastric 
pH .4 on Day 5 was significantly increased following esome-
prazole 20 mg compared with lansoprazole 15 mg (50.4% vs 
43.0%; P = 0.03) and rabeprazole 10 mg (59.8% vs 51.7%; 
P = 0.01).17 However, rabeprazole at 20 mg increased intra-
gastric pH compared with esomeprazole at 20 mg on Day 1 
and showed a higher AUC and intragastric pH on Day 118 
while also producing greater acid suppression on Day 1 than 
esomeprazole at 40 mg, particularly at night.19 Findings from 
these studies suggest that rabeprazole has a faster onset of acid 
inhibitory action than esomeprazole at either 20 or 40 mg from 
Day 1,19 although esomeprazole remains the most effective 
PPI from Day 5.20 Physicians should therefore consider the 
time and onset of treatment when selecting a PPI.
PPI-metabolizing enzyme  
CYP2C19 and its genotypes
PPIs undergo extensive hepatic metabolism by the CYP sys-
tem (Figure 2).21 Given that the principal enzyme related to 
the metabolism of PPIs is CYP2C19, it follows then that poly-
morphisms in CYP2C19 influence PPI pharmacokinetics and 
pharmacodynamics. Although more than 20 variant alleles 
of CYP2C19 have been identified, in Japanese the majority 
of individuals can be classified into the three genotypes, 
rapid extensive metabolizers (RMs), intermediate extensive 
metabolizers (IMs), and PMs, by identifying the CYP2C19 
wild-type (CYP2C19 *1) gene and the two mutated alleles, 
Table 1 Pharmacokinetic values for esomeprazole 20 mg
Dosage regimens Day S-omeprazole Racemic R-omeprazole
Hassan-Alin et al8 (Sweden) AUC (ng ⋅ hour/mL) 1 1.5 (0.9–2.5) 1.0 (0.6–1.7) 0.6 (0.4–1.0)
5 2.8 (1.7–4.8) 1.6 (1.0–2.8) 0.7 (0.4–1.2)
Cmax (µmol/L) 1 1.3 (0.9–1.8) 1.0 (0.8–1.4) 0.7 (0.5–1.0)
5 1.8 (1.3–2.6) 1.4 (1.0–2.0) 0.7 (0.5–1.0)
t1/2 (hour) 1 0.8 (0.6–0.9) 0.7 (0.5–0.8) 0.5 (0.4–0.6)
5 1.0 (0.8–1.2) 0.8 (0.6–1.0) 0.5 (0.4–0.7)
Andersson et al10 (Sweden) AUC (ng ⋅ hour/mL) 1 1.4 (1.0–2.3)
5 3.1 (2.1–4.6)
Cmax (µmol/L) 1 1.7 (1.3–2.2)
5 2.6 (2.0–3.2)
t1/2 (h) 1 0.7 (0.6–1.0)
5 1.1 (0.9–1.4)
AstraZeneca11 (Japan) AUC (ng ⋅ hour/mL) 1 3.2 (2.3–4.5)
5 6.0 (4.3–8.4)
Cmax (µmol/L) 1 1.4 (1.1–1.9)
5 2.6 (1.9–3.4)
t1/2 (h) 1 1.1 (0.9–1.3)
5 1.3 (1.1–1.5)
Notes: Maximum plasma concentration (Cmax; ng/mL), plasma half-life time (t1/2; hour), and area under the plasma concentration-time curve (AUC; ng ⋅ hour/mL) are given 
as median values (range).
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Figure 2 Metabolic pathways of esomeprazole, omeprazole, lansoprazole, rabeprazole, and pantoprazole in relation to cytochrome P450 isoenzymes, CYP2C19 and 
CYP3A4.
Note: weight of arrows indicates the relative contribution of different enzyme pathways.
CYP2C19*2 (*2) in exon 5 and CYP2C19*3 (*3) in exon 
4.13,21–23 Although an ultrarapid metabolizer (CYP2C19*17) 
has also been reported,24 its allele carrier incidence in Japan 
is much lower (2%) than in Western populations.25
Interethnic differences in the frequency of PMs are 
quite variable, with frequency among Asians being 
5–10 times that in other populations (2.5%–3.5% in 
Caucasians, 13.4%–19.8% in Chinese, 12.6% in Koreans, 
and 18.0%–22.5% in Japanese).12–14 Additionally, the Cmax 
and AUC values of a given PPI differ among the three 
major CYP2C19 genotype groups, with the highest values 
seen in PMs and lowest in RMs.16,26,27 Further, the metabolic 
clearance value in PMs is significantly lower than in RMs 
or IMs,16,26–28 while greater acid inhibition by PPIs can be 
observed in PMs due to differing pharmacokinetics in the 
genotype groups (Figure 3A–C).26–30
The in vitro formation of the 5-hydroxy and sulfone 
metabolites for both esomeprazole and R-omeprazole is 
mediated by CYP2C19 and CYP3A4.7 The proportion of 
the hydroxy metabolite from esomeprazole is less than that 
from R-omeprazole, while the proportion of the sulfone from 
esomeprazole is more, indicating that esomprazole is less 
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dependent on CYP2C19 than CYP3A4 for its metabolism 
than R-omeprazole. Because the clearance is 14.6 and 42.5 µL/
min/mg protein for esomeprazole and R-omeprazole,7 respec-
tively, the effect of esomeprazole may be less than 50% that of 
omeprazole depending on the genotype (Figure 1). Similarly, 
the contribution of CYP2C19 to systemic exposure seems 
more pronounced when using lansoprazole (AUC ratio of PM/
extensive metabolizer, 3.7–4.6) than esomeprazole (3.1).31
A Phase I study of esomeprazole in Japan showed that the 
AUC and Cmax in CYP2C19 PMs is higher than that in RMs or 
IMs (Table 2).11 Because the gastric acid suppression attained 
by PPI is correlated to total drug exposure, these differences 
should be considered when treating with esomeprazole.
Treatment for peptic ulcers
The neutralization of intragastric pH levels using appropri-
ate medications is important in treating peptic ulcers and 
prevention of rebleeding from peptic ulcers.32 Low-dose 
aspirin (LDA) is associated with adverse gastrointestinal 
effects, particularly in patients with increased gastrointes-
tinal risk, which includes the elderly, those with a history 
of peptic ulcers, and those receiving concomitant treatment 
with other anti-platelet or anti-coagulant drugs.33,34 In blinded 
treatment with esomeprazole at 20 mg or placebo for 26 
weeks, the former was found to significantly reduce the 
cumulative proportion of patients developing LDA-induced 
peptic ulcers (1.1% of patients receiving esomeprazole and 
7.4% receiving placebo).35 Similarly, Yeomans et al reported 
that 5.4% of patients receiving placebo (n = 27/498) devel-
oped LDA-induced peptic ulcers within 26 weeks compared 
with 1.6% of those receiving esomeprazole 20 mg (1.6%, 
n = 8/493).36 Further, Goldstein et al37 reported that esome-
prazole 20 mg was more effective in healing gastric ulcers 
and better tolerated in 406 patients who needed to continue 
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Figure 3 The 24-hour intragastric pH profiles after omeprazole 20 mg, lansoprazole 30 mg or rabeprazole 10 mg, od as a function of the CYP2C19 genotype group (A), and 
median 24-hour intragastric pH values in standard dose of PPI (B) and median 24-hour intragastric pH values in omeprazole, lansoprazole, or rabeprazole among different 
CYP2C19 genotype status (C).
Notes: *p  0.05 (vs. CYP2C19 RM); **p  0.05 (vs. CYP2C19 IM).
Abbreviations: RM, rapid extensive metabolizer; IM, intermediate extensive metabolizer; PM, poor metabolizer; PPI, proton pump inhibitor; od, once daily dose.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
53
Esomeprazole in JapanClinical and Experimental Gastroenterology 2012:5
NSAID therapy (122/138, 88.4%, 95% confidence interval 
[CI]: 83.1%–93.7%) than ranitidine 150 mg bid (98/132, 
74.2%; 95% CI: 66.8%–81.7%). Consequently, in Western 
populations, an esomeprazole dose of 20 mg appears to 
reduce the risk of peptic ulcers and symptoms associated 
with the continuous use of LDA or NSAIDs.
In Japan, esomeprazole at 20 mg od for 4, 12, and 
24 weeks in 168 patients treated with NSAIDs (n = 176) 
prevented the development of peptic ulcers in 99.4% 
(95% CI: 98.2%–100%), 96.7% (93.8%–99.5%), and 96.0% 
(92.8%–99.1%), respectively, which are all significantly 
higher than placebo effects (4 weeks: 78.8%, 95% CI: 
72.6%–85.0%; 12 weeks: 69.4%, 95% CI: 62.3%–76.6%; 
and 24 weeks: 64.4%, 95% CI: 58.6%–71.9%; P  0.001).11 
Further, the preventive effects for NSAIDs-induced peptic 
ulcers did not depend on the CYP2C19 genotype (96.8% 
[90.6%–100.0%] in RMs, 95.7% [91.0%–100.0%] in IMs, 
and 95.8% [90.2%–100.0%] in PMs).11 Given these findings, 
esomeprazole 20 mg appears sufficient to reduce the onset of 
peptic ulcers in Japanese patients using LDA or NSAIDs.
Treatment for GERD
GERD, which often includes an endoscopic mucosal break 
in the esophagocardial (EC) junction and acid reflux-related 
symptoms, is a common disease that is estimated to affect 
around 20%–30% of the population worldwide.38 In Japan, 
although the incidence of reflux disease is increasing in 
Western countries, most Japanese cases of reflux disease 
are NERD.39–41 For effective treatment of erosive GERD 
using acid inhibitory drugs, intragastric pH over a 24-hour 
period should fall below 4.0 for no longer than 2–4 hours 
(less than 16.7% of 24 hours).42 However, we previously 
demonstrated that LDA-induced esophageal injury prevents 
or reduces acid inhibition (24-hour intragastric pH .5.0 and 
pH 4.0 less than 40% of the time) when using a PPI.43
In general, esomeprazole is more effective than omepra-
zole when treating erosive GERD patients.44,45 A 6-month 
randomized, double-blind, placebo-controlled trial investi-
gating 375 GERD patients in the United States found respec-
tive recovery rates of 78.7%, 54.2%, and 29.1% for patients 
receiving esomeprazole 20 mg, esomeprazole 10 mg, and 
a placebo.46 Although PPI response in patients with NERD 
is less effective than those with erosive GERD,47 Chinese 
patients with NERD showed improved reflux-related symp-
toms when treated with esomeprazole.48
However, other studies have shown that esomeprazole is 
no more effective than other PPIs when treating GERD. In 
a multicenter double-blind trial of esomeprazole or omepra-
zole at 20 mg, the cumulative healing rates at Week 8 in 
patients with erosive GERD were approximately equal at 
90.6% and 88.3%, respectively.49 In clinical trials comparing 
rabeprazole 10 mg and esomeprazole 20 mg for NERD in 
Asian populations, no differences were seen with regard to 
the primary endpoint of time to achieve a 24-hour symptom-
free interval for heartburn (8.5 vs 9 days) or regurgitation 
(6 vs 7.5 days).50
The cumulative healing rates of esomeprazole 20 mg 
during 4, 12, and 24 weeks for Japanese GERD patients are 
97.8% (95% CI: 95.7%–99.9%), 95.0% (91.8%–98.2%), 
and 92.0% (88.0%–96.0%), respectively.11 The effect of 
esomeprazole 20 mg at 24 weeks is significantly higher 
than esomeprazole 10 mg (82.7%, 95% CI: 77.2%–88.3%; 
P = 0.007).11
After oral treatment for 4 weeks with esomeprazole 
40 mg, the proportion of RMs, as well as IMs/PMs, is 
similar between the groups with complete remission and 
incomplete healing of GERD.51 Additionally, multivariate 
analysis showed that the esomeprazole effect is not depen-
dent on the CYP2C19 genotype for complete and incomplete 
endoscopic healing.
H. pylori eradication therapy  
in Japan
In Japan, eradication of H. pylori is performed for patients 
with peptic ulcers, mucosa-associate lymphoid tissue lym-
phoma, idiopathic thrombocytopenic purpura, and early 
gastric cancer resected by endoscopy.52 The first-line regimen 
for eradication consists of a PPI administered bid, amoxi-
cillin at 750 mg bid, and clarithromycin at 200 or 400 mg 
bid for 1 week, while the second-line regimen consists of 
a PPI bid, amoxicillin at 750 mg bid, and metronidazole at 
Table 2   Pharmacokinetic  values  for  esomeprazole  20  mg  in 
relation to CYP2C19 in Japanese11
Dosage regimens RM IM PM
AUC (µmol ⋅ hour/L)
  Study 1 3.3 (2.2–5.0) 7.3 (4.7–11.4) 9.2 (7.2–11.8)
  Study 2 3.4 (2.5–4.6) 6.0 (4.7–7.7) 1.3 (1.1–1.5)
Cmax (µmol/L)
  Study 1 1.7 (1.1–2.8) 3.0 (1.9–4.7) 3.3 (2.8–3.8)
  Study 2 1.9 (1.5–2.4) 2.4 (2.0–3.0) 2.5 (1.6–3.8)
t1/2 (hour)
  Study 1 0.9 (0.7–1.1) 1.3 (1.0–1.7) 1.6 (1.3–1.9)
  Study 2 0.9 (0.8–1.1) 1.3 (1.1–1.5) 1.4 (1.1–1.7)
Notes: Maximum plasma concentration (Cmax; ng/mL), plasma half-life time (t1/2; hour), 
and area under the plasma concentration-time curve (AUC; ng ⋅ hour/mL) are given 
as median values (range).
Abbreviations: RM, rapid metabolizer of CYP2C19; IM, intermediate metabolizer; 
PM, poor metabolizer.
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250 mg bid for 1 week.53 Major causative factors associ-
ated with eradication failure include bacterial resistance to 
clarithromycin53 and insufficient gastric acid inhibition dur-
ing treatment.4 Indeed, a recent increase in the prevalence of 
clarithromycin-resistant strains in Japan to more than 30% 
has been accompanied by a reduction in eradication rates 
with the clarithromycin-based regimen.53–55
importance of gastric acid inhibition  
for H. pylori eradication
As mentioned above, efforts to eradicate H. pylori often fail 
due to insufficient acid inhibition. Because clarithromycin 
and amoxicillin are acid-sensitive, acid secretion must be 
potently inhibited by a PPI to prevent their degradation at 
low pH.56 Such potent acid inhibition increases the stabil-
ity and bioavailability of antibiotics in the stomach and 
also increases the concentration of antibiotics in gastric 
mucosa.57–59 For example, raising the pH from 3.5 to 
5.5 increases the in vitro effectiveness of amoxicillin more 
than 10-fold.57 Additionally, acid inhibition allows H. pylori 
to reach its growth phase, rendering the bacteria more sensi-
tive to antibiotics.59
We previously reported that the pH level over a 24-hour 
period was significantly higher in patients who achieved 
successful eradication using lansoprazole plus   amoxicillin/
clarithromycin as a first line-treatment (6.4 [5.0–7.6]) 
than those who did not (5.2 [2.2–6.2]), and that when the 
  percent-time for pH  4 was 10% and the 24-hour pH 
level was .6.0, we were able to achieve eradication in a 
  majority of patients, irrespective of the bacterial suscepti-
bility to clarithromycin.4 As a corollary, when using a PPI/
amoxicillin/clarithromycin regimen, the longer the period 
of elevated pH during treatment, the higher the eradication 
rates. In our unpublished data, intragastric pH and percent-
time of pH  4 on esomeprazole 20 mg bid in H. pylori-
negative, healthy young volunteers with high acid secretion 
were 5.4 (5.2–6.1) and 25.6% (15.0%–31.2%) (Figure 4). 
These   findings strongly suggest that esomeprazole can effec-
tively eradicate H. pylori in Japanese populations provided 
  sufficient acid inhibition is achieved.
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Figure 4 The 24-hour intragastric pH profile (A), median intragastric pH value (B), and percent time with pH  4 (C) during esomeprazole 20 mg bid treatment for 7 days.
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Esomeprazole-based H. pylori eradication 
therapy
A randomized study from Taiwan shows that the eradication 
rate when treated with clarithromycin 500 mg, amoxicillin 
1 g, and esomeprazole 40 mg bid for 1 week is 86% in the 
intention-to-treat (ITT) population.60 First-line H. pylori 
eradication therapy with levofloxacin/amoxicillin plus 
esomeprazole at 20 mg bid in Chinese patients was 85.2% 
effective.61 Further, the eradication rate by ITT analysis 
was 74.0% with clarithromycin at 500 mg, amoxicillin 
1000 mg, and esomeprazole 20 mg bid for 7 days; 78.0% 
using the same antibiotics plus esomeprazole 40 mg bid for 
7 days; and 80.0% for 10 days.62 That report also suggested 
that neither esomeprazole dosage nor dosing duration have 
additive effects on H. pylori eradication rates. Although 
some reports have shown that esomeprazole at 20 mg has 
an H. pylori eradication rate similar to that of omeprazole at 
20 mg,63,64 the rate has also been shown to significantly differ 
between esomeprazole-based and other PPI-based regimens, 
such as pantoprazole-based treatment (ITT analysis: 94% 
vs 82%; P = 0.009).65
Influence of CYP2C19 polymorphisms  
on esomeprazole-based H. pylori  
eradication therapy
In Japanese populations, the eradication rates of H. pylori by 
PPI-based eradication therapy differ by CYP2C19 genotype.66,67 
Indeed, eradication rates with triple therapy of PPI bid, 
amoxicillin 250 mg three times daily (tid), and clarithromycin 
200 mg tid for 1 week were 72.7% in RMs, 92.1% in IMs, 
and 97.8% in PMs.55 Further, a standard first-line regimen 
showed eradication rates of 57.7% in RMs, 71.6% in IMs, 
and 91.7% in PMs.68 Meta-analysis has shown the absolute 
risk of genetic differences in eradication failure by PPI-based 
regimens.51 Taken together, these reports demonstrate that 
one reason for the failed eradication by PPI-based therapy is 
insufficient acid inhibition in CYP2C19 RMs.
However, eradication rates with esomeprazole-based 
treatment (20 mg and 40 mg bid) have been shown to be 
independent of CYP2C19 genotype (RM: 87%, IM: 93%, 
and PM: 92% in one study;69 and RM: 93%, IM: 93%, and 
PM: 95% in another).60 Pan et al61 reported similar findings 
using esomeprazole/levofloxacin/amoxicillin in Chinese 
populations (RM: 82% [41/50], IM: 82% [50/61], and PM: 
89% [32/36]). In general, no previous reports have found 
significant differences in eradication rate for esomeprazole-
based treatment among CYP2C19 genotypes.
Interestingly, although eradication rates are significantly 
higher in esomeprazole-based regimens than omeprazole-
based ones (93% vs 76%; P  0.05), this advantage is 
observed only in RMs.60 Esomeprazole at 40 mg bid for triple 
therapy may improve the H. pylori eradication compared to 
omeprazole-based therapy, but likely only in CYP2C19 RMs, 
as the eradication rates between omeprazole-based and esome-
prazole-based regimens are similar in IMs and PMs.60
Summary
Compared to omeprazole, esomeprazole is a popular PPI with 
a better pharmacokinetic profile for the treatment of acid-
related diseases, has a higher AUC, and less interindividual 
variability. However, due to its relatively recent release in 
Japan, little data are available on its efficacy in Japanese 
patients. Nevertheless, findings in other populations suggest 
that esomeprazole will be effective in treating peptic ulcers, 
GERD, and H. pylori in Japanese populations, too.
Because CYP2C19 RM in Japanese is only 30%, which 
is significantly lower than that in Western population (70%), 
it is unclear whether this factor means that the clinical results 
from the treatment of esomeprazole in Japanese are signifi-
cant. However, this factor cannot ignore acid-related disease, 
because the prevalence of GERD, NERD, and LDA-related 
peptic ulcer, which require more potent acid inhibition, is 
increasing in Japan and a cure rate of GERD and peptic ulcer 
by PPI treatment differed among Japanese with different 
CYP2C19 genotype status.3,70 Further study will be required 
to increase new knowledge of esomeprazole in Japanese.
Key points
•  Esomeprazole is now used as a first-line drug for the 
treatment of acid-related diseases such as peptic ulcers, 
GERD, NERD, Zollinger–Ellison syndrome, and 
H. pylori infection in the world.
•  Esomeprazole is the first PPI developed as a single 
isomer, and its metabolism is less dependent on CYP2C19 
than CYP3A4 compared to R-omeprazole.
•  Although the clearance of esomeprazole is approximately 
50% less than omeprazole, the efficacy of esomepra-
zole on different CYP2C19 genotypes should not be 
completely ignored.
•  CYP2C19 RM patients in particular should be assigned 
esomeprazole-based treatment against acid-related 
diseases.
•  In Japan, the standard dose of esomeprazole for treatment 
is 20 mg od, whereas the standard dose in most Western 
countries is 40 mg od.
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